🇺🇸 FDA
Patent

US 12202832

Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

granted A61KA61K31/4184A61K31/519

Quick answer

US patent 12202832 (Heterocyclic compounds having a calcium-sensing receptor antagonistic activity) held by Takeda Pharmaceutical Company Limited expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/4184, A61K31/519, A61K47/38, A61K9/2013